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To the Editor:
We would like to comment on sur-
gical management of the lung in the
United Kingdom for the period from
2004 to 2009. Surgical management
offers can be curative but there are
little data on the subsequent prognosis
of patients in the United Kingdom.
Pneumonectomy and lobectomy have
reported mortality rates of 6% to
8% and 2% to 4%, respectively.1-4
Our study aimed to assess diagnostic
methods, staging, and long-term prog-
nosis in surgically managed patients
with lung cancer. We retrospectively
analyzed the medical notes of all
surgically managed lung cancer
patients in a National Health Service
hospital between 2004 and 2009. Only
40 patients were identified, 80% had
non–small-cell lung cancer and in the
remaining patients no tissue diagnosis
was made. Ninety percent were staged
node negative via a combination of
both positron emission tomography
and computerized tomography scan-
ning. No patients received preoperative
down-staging adjuvants.
Mortality rates at both 6 months and
1 year was 25%. There were no surgi-
cal deaths or deaths in the immediateThe Journalpostoperative period. All patients
who died within 6 months of surgery
had radiologic evidence of metastatic
disease and lung cancer specified on
theirmedical cause of death certificate.
Thirty percent of patients received
postoperative chemotherapy, 3% of
patients received postoperative radio-
therapy, and 6% of patients received
both chemotherapy and radiotherapy.
In the patients who died, the median
survival time was 5.3 months. Three
of the 10 patients who died had evi-
dence of metastatic thoracic disease
at surgery. Tumor staging was compa-
rable between those who died and
those who were cured.
In conclusion, surgicalmanagement
was curative (defined as no evidence of
metastatic disease at 1 year postopera-
tively) in 30 patients (75%). In those
patientswhowere not cured, prognosis
was poor and comparable with those
who did not have surgery. Tumor
staging did not affect outcome.
Our study was largely historical and
showed practice before the update to
the guidelines in 20115 such that
now patients undergoing surgery
with curative intent should first have
hilar and mediastinal lymph node
sampling, or otherwise undergo bloc
resection. Second, many of our pa-
tients proceeded to surgery without
histologic evidence of disease. Ob-
taining histologic proof can be diffi-
cult; tumors on the periphery of the
lung cannot be visualized with con-
ventional bronchoscopy but the new
guidelines have evolved to include en-
dobronchial ultrasound (EBUS),
which may reduce the number of tho-
racotomies occurring without priorof Thoracic and Cardiovascular Surgehistologic diagnosis. The limitations
to our study stem from our limited
number of cases, poorly maintained
registry, and its historical nature. How-
ever, we hope this letter encourages
others to perform a larger study that
examines the effects of EBUS and pre-
operative staging on results. This is
very important because the costs in-
volved in creating an EBUS service
are significant and must be justified
in the context we have outlined.
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